Pharmaceutical giant Pfizer has issued a statement regarding an ongoing investigation into counterfeit medication in the Indian state of Karnataka. The company emphasized that its primary focus remains the protection of patients and the preservation of public health standards. According to the company, they are working in close coordination with local authorities to address open queries related to the probe.

The investigation centers on the discovery of fake drugs circulating within the region, which has prompted concerns regarding supply chain integrity and consumer safety. While Pfizer has publicly committed to maintaining confidence in the healthcare system, the company has not provided specific details regarding the origin of the counterfeit products or the extent of their involvement in the investigation. The situation remains fluid as regulatory bodies continue to examine the distribution networks involved in the case. Pfizer’s statement serves as a formal response to the scrutiny surrounding the pharmaceutical industry's role in ensuring that patients receive authentic, safe medication. As the probe continues, the company maintains that it is prioritizing the resolution of all outstanding questions raised by the authorities.